Abstracts tagged "tocilizumab and giant cell arteritis"

Abstract Number: 808 • 2019 ACR/ARP Annual Meeting
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
John Stone¹, Min Bao ², Jian Han ², Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Sebastian Unizony ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Tocilizumab (TCZ) 162 mg administered subcutaneously weekly (QW) or every-other-week (Q2W) plus 26-wk prednisone tapering resulted in higher rates of sustained glucocorticoid (GC)–free remission…
Abstract Number: 1838 • 2019 ACR/ARP Annual Meeting
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
John Stone¹, Helen Spotswood ², Sebastian Unizony ¹, Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Min Bao ¹¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) administered subcutaneously every week (QW) or every other week (Q2W) with 26-week prednisone tapering was superior to placebo (PBO) plus 26-week (PBO+26)…
Abstract Number: 1840 • 2019 ACR/ARP Annual Meeting
Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone
Sebastian Unizony¹, Min Bao ², Jian Han ², Yves Luder ³, Páris Sidiropoulos ², Jinglan Pei ² and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Risk factors for treatment failure in patients with giant cell arteritis (GCA) are poorly understood. The objective of this analysis was to identify predictors…
Abstract Number: 2663 • 2019 ACR/ARP Annual Meeting
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
John Stone¹, Jian Han ², Sebastian Unizony ¹, Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Min Bao ², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) plus prednisone tapering achieved higher rates of sustained glucocorticoid (GC)-free remission and had lower…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].